FacebookTwitterGoogle+RedditEmail

Molecule of the Year: Cannabiodiol

by FRED GARDNER

THC -delta-9 tetrahydrocannabinol- is not the only active ingredient in cannabis. At least five other cannabinoids exhibit biological activity, and so do some terpenes and flavonoids. All these compounds are found in the resin stored in the plant’s glandular trichomes. They are chemically related.

THC predominates in plants bred for psychoactivity (as cannabis plants have been bred for generations in California and elsewhere). Cannabidiol -CBD- is the predominant cannabinoid in plants typically bred for fiber. There are only trace quantities of CBD in high-THC plants because one form of the same gene codes for THC synthase and the other codes for CBD synthase. Thus growers selecting for high THC content get low CBD.

California growers hoping to develop plants with a high CBD-to-THC ratio have been stymied by lack of access to an analytical test lab. In surreptitious tests, “high grade” buds were reportedly in the range of 15-20% THC and 0.1% CBD.

The U.S. Drug Enforcement Administration has placed CBD on Schedule I even though CBD has no known adverse effects and doesn’t induce “euphoria.” The most dire effects attributed to marijuana -tachycardia (accelerated heartbeat), panic, confusion, anxiety, even psychosis- are effects of THC that CBD has been shown to mitigate!

By listing CBD as a Schedule 1 substance and denying growers the means to develop high-CBD plant strains, the government is protecting the American people from an immunomodulator with anti-inflammatory, anti-convulsant, anti-psychotic, anti-oxidant, and neuro-protective properties. In whose interests could that possibly be?

BF Mechoulam on CBD END BF

The chemist who worked out the precise structure of CBD 45 years ago, Raphael Mechoulam, gave a “review talk” at this year’s meeting of the International Association for Cannabis as Medicine. Mechoulam had just gotten his PhD in chemistry in the Fall of ’62 and was looking for a research project that might lead to tenure at the Weizmann Institute. He chose to analyze the components of cannabis, he said, thinking “it’s a minor project, it will be finished off in six months.”

Hashish of Lebanese origin was obtained from the police -“There is a fantastic collaboration between Arabs and Jews in smuggling,” Mechoulam observed- and a dozen constituents were then identified by two types of chromatography. (Some cannabis constituents had been identified previously, including CBD, which Roger Adams of the University of Illinois isolated in the early 1940s.)

It was generally assumed throughout the ’60s and ’70s that the cannabinoids exerted effects not by binding to a specific receptor but “nonspecifically” by altering the lipid structure of cellular membranes. Mechoulam established that the action was specific by purifying THC and showing that only the natural version of the molecule -and not its synthetic mirror image- was exerting the effect. In 1988 Alynn Howlett found that THC was indeed activating a receptor. It was dubbed “CB1” and was found in those areas of the brain involved in movement, stress, cognitive function – “everywhere it would be expected,” said Mechoulam, given what was known about the effects of cannabis on people.

Unlike THC, CBD hardly binds to the CB1 receptor. It binds to a second cannabinoid receptor -CB2-originally found in spleen cells by S. Munro of Cambridge University in 1993 and subsequently found in the stomach, liver, heart, kidney, lymph and immune cells, bones, endocrine glands, and throughout the peripheral nervous system.

In his IACM talk Mechoulam reviewed research in recent years that has shed light on aspects of CBD’s mechanism of action. Its lipid-solubility enables it to get into places in the brain that conventional neurotransmitters cannot reach. It is a potent anti-oxidative agent. It turns out to be an antagonist to a recently discovered receptor called GPR-55 to which THC and 2-AG bind as agonists. It blocks the uptake of adenosine, an inhibitory neurotransmitter that may promote sleep. It blocks the formation of various cytokines (signaling compounds not released by nerves or glands) under certain circumstances. It activates the serotonin receptors. No wonder, then, that CBD plays a role in many clinical conditions.

Conditions treatable by CBD

Mechoulam described an experiment led by Paul Consroe and colleagues in Brazil in which CBD was tested as a treatment for intractable epilepsy. Patients stayed on the anticonvulsants they had been on (which hadn’t eliminated their seizures) and added 200mg/day of CBD or a placebo. Of the seven patients getting CBD over the course of several months, only one showed no improvement; three became seizure-free; one experienced only one or two seizures, Mechoulam recalled; and two experienced reduced severity and occurrence of seizures.

“So it seemed a very promising approach,” said Mechoulam, “but unfortunately, nothing has been done ever since. To the best of my knowledge, nobody has done any work on cannabidiol in the clinic on epilepsy, and I wonder why.”

A colleague of Mechoulam’s, Marc Feldman at Imperial College, London, tested CBD on mice who had a version of rheumatoid arthritis and found that it reduced inflammation by almost 50% at the right dose -5mg/kg of body weight. But this “beautiful antiinflammatory reaction was lost if we went up to, say, 25 mg/kg,” Mechoulam said. Drug developers must bear in mind and cope with the fact that cannabinoids have a finite “therapeutic window” -they are ineffective at low and high doses.

Mechoulam has been testing CBD on mice bred to have a version of type-1 diabetes that manifests around age 14 weeks. He and his co-workers treated these mice with CBD for their first 6-7 weeks of life, then tested them 6-7 weeks later and found that only 30% had developed diabetes (compared to 90-100% given placebo).

In a follow-up experiment the mice weren’t given a course of CBD until age 14 weeks, when they were developing diabetes. They were then tested at age 24 weeks, and again only 30% of the treated mice were found to have diabetes. In other words, CBD did not just prevent onset but blocked development of diabetes.

Examination of the insulin-producing islets showed that only 8% were intact in the untreated diabetic mice, whereas 77% were intact in the mice treated with CBD. “I believe that here we have something very promising,” Mechoulam said. “We plan to have a clinical trial starting next week treating patients, and hopefully at the next meeting I will tell you that all of them are cured.”

Cardiologists working with mice at Hebrew University have found that CBD treatment at the time of a heart attack can reduce infarct size by about 66%. “So now they’re pushing me, ‘let’s have more CBD,'” Mechoulam said. “We should try it with humans in a few years.”

He went on: “What about sleep? I’m jumping from thing to thing to show you that CBD does quite a lot of things and I’m not sure that all of them are according to the same mechanism.” Mechoulam was part of a group led by Eric Murillo-Rodriguez that administered CBD to rats and determined that while THC caused sleepiness, CBD increased wakefulness and significantly decreased REM sleep. According to Mechoulam, “When one says ‘cannabis causes sleep,’ one should think really of two compounds, one that causes sleep and one that causes awakening.”

The anti-nausea and memory extinction effects of CBD “seem to be closely related,” Mechoulam said. He described the problem of anticipatory nausea, for which no good drugs are available. (The effects of chemotherapy can be so nauseating that patients start vomiting when they see the doctor or nurse who is going to administer the treatment.) Linda Parker at the University of Guelph conditioned shrews to start vomiting by administering lithium fluoride at a certain location. When the shrews were subsequently placed in that location they began vomiting. But if given CBD, they could be moved to the dreaded location without vomiting. “The conditioned-wretching reaction was completely abolished,” Mechoulam declared. [THC is anti-emetic, too; the advantage of CBD in this instance may be legal rather than medical.]

Mechoulam is hopeful that CBD can help tone down other kinds of conditioning. He described an experiment in which rats had a choice of two paths, one leading to cocaine, one to no reward. Rats like cocaine (and amphetamine) and will learn to choose the path leading to it. But if injected with CBD, they no longer show a preference for cocaine! Mechoulam characterized post-traumatic stress disorder, certain phobias and forms of chronic pain as “human situations which are conditioned” and might be amenable to treatment with CBD. “I know that many patients with PTSD take cannabis, self administered,” Mechoulam said. He has been trying to interest the Israeli Ministry of Health in testing CBD and THC at various ratios to treat PTSD.

FRED GARDNER will be opening for a band called Lake Street at the Rockitt Room (formerly the Last Day Saloon, Clement St. off 6th Ave.) Sunday, Nov. 25, 8 p.m. He can be reached at fred@plebesite.

 

 

Fred Gardner is the managing editor of O’Shaughnessy’s. He can be reached at fred@plebesite.com

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

March 22, 2017
Paul Street
Russiagate and the Democratic Party are for Chumps
Russell Mokhiber
Single-Payer, the Progressive Caucus and the Cuban Revolution
Gavin Lewis
McCarthyite Anti-Semitism Smears and Racism at the Guardian/Observer
Kathy Kelly
Reality and the U.S.-Made Famine in Yemen
Kim C. Domenico
Ending Our Secret Alliance with Victimhood: Toward an Adult Politics
L. Ali Khan
Profiling Islamophobes
Calvin Priest
May Day: Seattle Educators Moving Closer to Strike
David Swanson
Jimmy Breslin on How to Impeach Trump
Dave Lindorff
There Won’t Be Another Jimmy Breslin
Jonathan Latham
The Meaning of Life
Robert Fisk
Martin McGuinness: From “Super-Terrorist” to Super Statesman
Steve Horn
Architect of Federal Fracking Loophole May Head Trump Environmental Council
Binoy Kampmark
Grief, Loss and Losing a Father
Jim Tull
Will the Poor Always Be With Us?
Jesse Jackson
Trump’s “March Massacre” Budget
Joe Emersberger
Rafael Correa and the Future of Ecuador: a Response to James McEnteer
March 21, 2017
Reshmi Dutt-Ballerstadt
On Being the “Right Kind of Brown”
Kenneth Surin
God, Guns, Gays, Gummint: the Career of Rep. Bad Bob Goodlatte
David Rosen
Popular Insurgencies: Reshaping the Political Landscape
Ryan LaMothe
The Totalitarian Strain in American Democracy
Eric Sommer
The House Intelligence Committee: Evidence Not Required
Mike Hastie
My Lai Massacre, 49 Years Later
James McEnteer
An Era Ends in Ecuador: Forward or Back?
Evan Jones
Beyond the Pale
Stansfield Smith
First Two Months in Power: Hitler vs. Trump
Dulce Morales
A Movement for ‘Sanctuary Campuses’ Takes Shape
Pepe Escobar
Could Great Wall of Iron become New Silk Roadblock?
Olivia Alperstein
Trump Could Start a Nuclear War, Right Now
David Macaray
Norwegians Are the Happiest People on Earth
March 20, 2017
Michael Schwalbe
Tears of Solidarity
Patrick Cockburn
Brexit, Nationalism and the Damage Done
Peter Stone Brown
Chuck Berry: the First Poet of Rock and Roll
Paul J. Ramsey
What Trump’s Travel Ban Reveals About His Long-Term Educational Policy
Norman Pollack
Two Nations: Skid Rows vs. Mar-a-Lago
Michael Brenner
The Great Game: Power Politics or Free Play?
Sam Gordon
Falling Rate of Profit, What about Some Alienation?
Jack Random
Sidetracked: Trump Diaries, Week 8
Julian Vigo
The Limits of Citizenship
James Graham
French Elections: a Guide for the Perplexed
Jeff Mackler
The Extraordinary Lynne Stewart
Lee Ballinger
Chuck Berry: “Up in the Morning and Off to School!”
Binoy Kampmark
Romancing Coal: The Adani Obsession
Nyla Ali Khan
Cultural Syncretism in Kashmir
Chad Nelson
The Politics of Animal Liberation: I Can’t Quit You Gary Francione
Weekend Edition
March 17, 2017
Friday - Sunday
John Reynolds
Israel and the A-Word
FacebookTwitterGoogle+RedditEmail